outperform price
thesi updat guess said done
tool one best print rel
expect number idiosyncrat posit
aid core primarili relat seri savvi
acquisit superior execut pall biotech notabl
strong given materi invest biolog product
global cepheid straight crush sever front
modest sign global macro slowdown impact
pall microelectron turn neg frankli
caution flag waiv far fy
core guid rais improv omx despit need
invest ultim close ge transact
stori set-up remain compel bar set quit
high ultim think clear mayb even
eas would caution paint broadli across
tool quit yet certainli work quit hard
justifi inflect rel valuat could sustain
core growth could prove msd hsd
reiter outperform rais pt
growth rais previous
ea face tough comp busi track
ep rais previous
growth
ep
msd-hsd china tough comp
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
china underli condit strong overal
dx mid-teen growth
beckman well
msd due tough comp mid-teen growth last year
order trend packag strong
real soft industri exposur total rev might read given make-up
weak micro lsd larg expect given variou macro trend
 strong
videojet lsd-msd hsd comp
volum trend improv new product launch
dx upsid driven cepheid still earli day infecti diseas sexual health flu
geograph penetr strong china small base
small molecul growth still strong
larg molecul driven market growth
pall driven singl use technolog
bioreactor sourc growth
ct/gt still earli days/hug opportun zolgensma earli indic success within
db flywheel drive growth cphd
beckman hsd flow cytometri particl count viacel
sciex msd
pall msd
microelectron declin due tough comp
dd driven broad-bas strength product geographi
lb core msd stain histolog
radiometri strong blood ga aqt
cepheid driven high growth market new account penetr
solid demand municip industri end market
strong result food beverag oil ga
new product cadenc all-tim best level histolog stain
ge busi look strong debt financ look ideal time rate stay low real updat time
small mol/larg mol busi profit ct/gt expect solid well time
win rate pall impact ge deal
beckman hematolog complet redon improv retent win rate consist improv last
doesnt huge cross-sel opportun given stand-alone model
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america
articl articl
time dissemin juli
analyst luke sergott jon bristow ross muken primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research report
